Research & Reviews Journal of Pharmacology & Toxicology Studies
e-ISSN: 2322-0139
p-ISSN: 2322-0120

Pharmacovigilance - A Review

Prachi Tyagi*

Department of Biotechnology, Graphic Era University, Dehradun, Uttarakhand, India

Review Article

Received: 08/02/2017
Revised: 10/03/2017
Accepted: 16/03/2017

*For Correspondence

Department of Biotechnology, Graphic Era University, Dehradun, Uttarakhand, India, Tel: +91 7534849483.

E-mail:
tyagiprachi14@gmail.com

Keywords: Pharmacovigilance, Drug safety, Clinical trials, Pharmaceutical, Drugs

ABSTRACT

The wellbeing worry of medication is currently turning into the need territory. The thalidomide disaster of 1960's opened the eyes of medication controllers and additionally other concern body to build up an approach to guarantee sedate security, already the issues was in shadow. The medication security issues were globalized, fortify and systematized after the foundation of World Health Organization (WHO) Program for International Drug Monitoring in 1968. Each medication is connected with gainful and also undesirable or antagonistic impact. Unfavorable medication responses (ADR) are the normal clinical issue. The hospitalization because of ADRs in a few nations is about or more than 10%. Furthermore, it is evaluations that 10-20% of the healing center inpatient experiences ADRs. Proper and successful checking of ADRs, i.e., pharmacovigilance, is the main most ideal approach to shield the general wellbeing. Unconstrained reporting framework (SRS) is the first and most generally utilized strategy to report ADRs as a part of resentment of under-reporting as a noteworthy restriction. It is empower to early identification of new, back and genuine ADRs. In light of those reported cases flag is produced. Flag is new conceivable causal connection between a suspected ADR and medication; which is beforehand obscure or not completely recorded. Disproportionality examination is most ordinarily utilized strategy for information cross examination to make sense of the relationship amongst medication and ADR of intrigue. The seriousness of under-reporting of ADRs is high; it appraises that lone 6% of ADRs are accounted for. There are many elements connected with under reporting of ADRs; arranged as staff and expert qualities of human services proficient and their insight and state of mind to ADR reporting. As far as ADR reporting information and states of mind of wellbeing experts is emphatically related. Under-reporting can be essentially enhanced by suitable instructive mediation.

INTRODUCTION

Pharmacovigilance (PV or PhV), otherwise called tranquilize wellbeing, is the pharmacological science identifying with the accumulation, discovery, appraisal, observing, and counteractive action of unfriendly impacts with pharmaceutical products [1-4]. The etymological roots for "pharmacovigilance" are: pharmakon (Greek for medication) and vigilare (Latin for to keep watch). Accordingly, pharmacovigilance vigorously concentrates on unfavorable medication responses, or ADRs, which are characterized as any reaction to a medication which is poisonous and unintended, including absence of adequacy (the condition that this definition just applies with the measurements regularly utilized for the prophylaxis, finding or treatment of sickness, or for the change of physiological issue capacity was avoided with the most recent correction of the appropriate legislation) [5-10]. Pharmaceutical bumbles, for instance, overdose, and manhandle and misuse of a prescription and also sedate presentation in the midst of pregnancy and breastfeeding, are similarly of interest, even without an unpleasant event, since they may realize an opposing solution response [5,11].

Data got from patients and social insurance suppliers through pharmacovigilance assentions (PVAs), and in addition different sources, for example, the medicinal writing, assumes a basic part in giving the information important to pharmacovigilance to happen [12-13]. Truth is told, so as to market or to test a pharmaceutical item in many nations, unfavorable occasion information got by the permit holder (typically a pharmaceutical organization) must be submitted to the neighborhood sedate administrative power [14-18].

Eventually, pharmacovigilance is worried with recognizing the dangers connected with pharmaceutical items and with minimizing the danger of any damage that may come to patients. Organizations must direct a complete

medication wellbeing and pharmacovigilance review to evaluate their consistence with overall laws, controls, and direction [19-22].

PHARMACOVIGILANCE and DRUG SAFETY MONITORING

ADR has characterized by WHO seems to be "harmful or unintended reaction to a medication happens at a standard measurement" [23,24]. ADR is comprehensively named Type A and Type B. Sort A response is connected with the pharmacological activities of the medication and is unsurprising while Type B response is not connected with the pharmacological activities of the medication and is not unsurprising. It is otherwise called quirky response [25-27]. Sort A response is more predominant, records for more than 80%, than the Type B reaction. ADRs are connected with noteworthy grimness and mortality. Late gauges propose ADRs are the fourth to 6th real reason for death in the United States of America (USA). The hospitalization because of ADRs in a few nations is about or more than 10%, which implies ADRs as a noteworthy reason for hospitalization. Moreover, it is assessments that 10-20% of the healing center inpatient experiences ADR [28]. That's why ADRs is the regular clinical issue. Suitable checking of ADRs is the main most ideal approach to shield the patients and even counteracts ADRs. The term pharmacovigilance is a French world, which has been depicted by Professor Bernard Begaud as "a teach including recognition, assessment and aversion of undesirable impacts of medicines" [29-32]. Another definition as portrayed by Professor Lawson is as "a feature of the investigation of pharmacoepidemiology". The WHO characterizes pharmacovigilance as "the science and exercises identifying with the identification, appraisal, comprehension and counteractive action of unfavorable impacts or whatever other conceivable medication related problems". The pharmacovigilance plans to early acknowledgment of beforehand obscure ADRs, acknowledgment of recurrence of known ADRs, distinguishing proof of hazard elements and component of ADRs, quantitative investigation of advantage/hazard proportion and dispersal of wellbeing data for objective medication recommending and direction [33-37]. The wellbeing information created amid the clinical trials is dependably insufficient to preclude all conceivable unfriendly impact of the medication, when they presented in this present reality [38-40]. The significant confinements of clinical trial are: creature tests are lacking to anticipate the human security, just chose patients are uncovered and restricted time span, constrained human subject, in all cases under 5,000, which is good to recognize just the more regular ADRs [41]. For the identification of uncommon and extremely uncommon ADRs expansive example size is required. For instance, to discover the rate of 1 in 10,000 no less than 30,000 individuals should be treated with a medication [42]. To distinguish the occurrence of 1 in 100,000, we can envision the specimen estimate, which are nearly past the extent of clinical trials [43-45]. This thusly, the wellbeing data accessible even by the very much planned clinical trials is not satisfactory to answer the security concern [46-48]. Subsequently, the pharmacovigilance; regularly demonstrates as post promoting reconnaissance by pharmaceutical organizations, as a methodical observing can be a successful approaches to recognize sedate related security issues for the duration of the life cycle of any medication [49-54].

BENEFIT- RISK ASSESSMENT

Chance/advantage evaluation is essential amid the entire life cycle of items. For every medication one must measure benefits against the dangers, frequently in particular sub-populaces [55,56]. Clinical trials give this data in light of a predetermined number of patients and for patients with certain qualities preceding endorsement [57-60]. Be that as it may, once another medication is utilized as a part of clinical practice by numerous patients, new antagonistic responses, e.g. extremely uncommon ones, may raise that had not been beforehand seen in clinical trials [61-64].

In this way, it is important to constantly screen the advantages and dangers of the medications once showcased to guarantee that the advantages still exceed the dangers [65-68]. YOLARX's broad aptitude in pharmacovigilance will permit you to set up the fitting exercises and apparatuses to recognize, survey, comprehend and counteract unfavorable responses and other medication related issues guaranteeing the patients' wellbeing [69-73]. For instance, we have created quantitative and semi-quantitative procedures for flag discovery that have passed administrative assessments [74-80].

CONCLUSION

Pharmacovigilance is the main way to guarantee the wellbeing of medication all through the lifecycle [81-83]. Its significance is in particular significant as the clinical trials have restriction to distinguish the uncommon and extremely uncommon ADRs. The learning and data accessible as to of any medication is in particular imperative to take fitting choice by sedate controllers to shield general wellbeing [84,85]. Human services experts are the principle reports of the ADRs; be that as it may, there are high rates of under-reporting reported universally [86]. It is the significant difficulties for now. Disregarding those confinements, unconstrained reporting framework stays as a

generally broadly utilized technique to report ADRs and can produce flag of uncommon and extremely uncommon sorts of ADRs [87-90]. On the off chance that all the medicinal services experts take ADR reporting as a moral commitments what's more, their real duties, we can make our reality more secure than what is today [91,92]. Each reporting by human services experts is essential; despite the fact that, concentrate on the genuine unlabelled sort of ADRs is more essential [93]. There are huge endeavors on the pharmacovigilance to make it more practical after the idea has developed; what's more, step by step we are nearer to the predetermination [94-97]. It is our obligations to guarantee phamacovigilance framework is working well. ADR reporting ought to be taken as an important obligation; not as an additional clinical trouble; by human services callings to guarantee the more secure medication use all through the world [98].

REFERENCES

1. Heidari A. A Pharmacovigilance Study on Linear and Non–Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for the Prediction of Retention Time of Anti–Cancer Nano Drugs under Synchrotron Radiations. J Pharmacovigil. 2016;4:e161.
2. Toklu HZ. Pharmacovigilance of Herbal Medicine: Herbavigilance. Adv Pharmacoepidemiol Drug Saf. 2016;5:208.
3. Ranjan A, et al. Signal Detection in Pharmacovigilance: An Application of Subjective Bayesian Inference. Adv Pharmacoepidemiol Drug Saf. 2016;5:207.
4. Reis CD, et al. Pharmacovigilance in Cabo Verde: Measuring the Impact of Pharmacovigilance Educational Campaign on Consumer's Knowledge. J Pharmacovigilance. 2016;4:217.
5. Muhannad RMS, et al. Physicians' knowledge about pharmacovigilance in Iraq. J Pharmacovigilance. 2016;4:214.
6. De Carvalho PM, et al. Brazilian Regulation in Pharmacovigilance: A Review. Pharmaceut Reg Affairs. 2016;5:164.
7. Gildeeva GN and Yurkov VI. Pharmacovigilance in Russia: Challenges, Prospects and Current State of Affairs. J Pharmacovigil. 2016;4:206.
8. Saygi S, et al. Pharmacovigilance Awareness among the Community Pharmacists and Pharmacy Students in the Turkish Republic of Northern Cyprus. J Pharmacovigil. 2016;4:204.
9. Reis CD, et al. Pharmacovigilance in Cabo Verde: Measuring the Awareness and Knowledge of Consumers. J Pharmacovigil. 2016;4:200.
10. Sanaa A, et al. Awareness and Perception of National Pharmacovigilance Center among Lebanese Medical Staff. J Pharmacovigilance. 2016;4:199.
11. Karampola MI and Emmanouilides CE. Pharmacovigilance for Biosimilars. J Pharmacovigil. 2016;4:196.
12. Tolentino MJ. Macular Supplements Containing Zinc and Vitamin A Should Be Replaced with Meso-Zeaxanthin, Lutein and Zeaxanthin: An Ophthalmic Need for Pharmacovigilance. J Pharmacovigil. 2016;4:195.
13. le Grand A, et al. Interventionresearchinrationaluseofdrugs: a review. Health Policy Plan. 1999;14:89-102.
14. World Health Organization (2002) Promoting rational use of medicines: core components-WHO Policy Perspectives on Medicine.
15. van Grootheest K and de Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf. 2004;3:363-368.
16. de Langen J, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31:515-524.
17. Reis CD, et al. Illegal Market of Medicines in Cabo Verde: Characterization for Action. J Pharmacovigil. 2015;3:1-5.
18. Maryam A (2016) Some Aspects of the Problem of Adulterated Herbal Medicines by the Illegal Addition of Active Pharmaceutical Ingredients. J Clin Toxicol 6:e124.
19. Luisetto M. Pharmaceutical Care and Toxicology, a Synergy in High Risk Situation. J App Pharm. 2016;8:231.
20. Luisetto M, et al. Management Instrument in Pharmaceutical Care and Clinical Pharmacy. Int J Econ Manag Sci. 2016;5:373.
21. Lea B, et al. Development of On- Line Solid-Phase Extraction-Liquid Chromatography Coupled with Tandem Mass Spectrometry Method to Quantify Pharmaceutical, Glucuronide Conjugates and Metabolites in Water. J Chromatogr Sep Tech. 2016;7:337.
22. Luisetto M. A New Management Healthcare Systems to Efficiently Reduce Healthcare Costs: Clinical Pharmaceutical Care, Medical Laboratory Imaging, Nuclear Medicine: A Synergy Instruments. J Bus Fin Aff. 2016;5:205.
23. Ibrahim F, et al. Micellar High Performance Liquid Chromatographic Method for Simultaneous Determination of Clonazepam and Paroxetine HCl in Pharmaceutical Preparations Using Monolithic Column. J Chromatogr Sep Tech. 2016;7:331.

24. Ghose R. Altered Expression/Activity of Cytochrome P450 (CYP) 3A4 Enzyme: Implications in Drug Safety and Efficacy. J Clin Trials. 2016;6:e123.
25. Patil JS. Drug Safety and Indian Pharmacist. Adv Pharmacoepidemiol Drug Saf. 2015;4:e131.
26. Patil JS. Pharmacoepidemiology and Drug Safety Concept:Indian Scenario. Adv Pharmacoepidemiol Drug Saf. 2015;4:e130.
27. Michiko Yamamoto. Risk Communication Regarding Drug Safety in Japan. Occup Med Health Aff. 2014;2:152.
28. Baan J, et al. Capecitabine-induced Toxicity: An Outcome Study into Drug Safety. J Integr Oncol 3:113.
29. Monte AA (2013) Drug Safety in the "Omics Era". J Drug Metab Toxicol. 2014;4:e119.
30. Neetu, Singhal HK, et al. Importance of Drug Safety and Efficacy W.S.R to Strychnos Nux Vomica Detoxification. J Homeop Ayurv Med. 2013;2:125.
31. Ganguly S. Pharmacoepidemiology and Drug Safety with Special Reference to Vaccines and Biologicals used as Diagnostics. Adv Pharmacoepidem Drug Safety. 2012;1:e118.
32. Midlöv P. How can we Improve Drug Safety When Treating Frail Elderly Patients? Adv Pharmacoepidem Drug Safety. 2012;1:e109.
33. Johnson DE. Predicting Drug Safety: Next Generation Solutions. J Drug Metab Toxicol. 2012;3:e106.
34. Ostapowicz G, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.
35. Jacob L, et al. Interests of Bayesian Approaches for the Analysis and Summary of Adverse Event Data Recorded in Randomized Phase III Clinical Trials. J Clin Trials. 2016;6:286.
36. Clivio L, et al. Beyond the Web: A Decentralised Approach to Data Collection from Multi-Centric Clinical Trials by Virtual Organizations Using Peer-To-Peer Data Sharing. J Clin Trials. 2016;4:275.
37. Liu Y. Opinion on Adaptive Designs in Clinical Trials. J Biom Biostat. 2016;7:310.
38. Delsing L, et al. Finding the Patients for Respiratory Clinical Trials; Successful Recruitment by Adapting Trial Design. Lung Dis Treat. 2016;2:110.
39. Lin J and Sankoh S. Response-Adaptive Randomization Design for Clinical Trials with Survival Outcomes. J Biom Biostat. 2016;7:302.
40. Lodha A. Globalization of Clinical Trials: Ethics and Conduct. J Biotechnol Biomater. 2016;6:229.
41. Lin J, et al. A General Overview of Adaptive Randomization Design for Clinical Trials. J Biom Biostat. 2016;7:294.
42. Lin J, et al. A Bayesian Response-adaptive Covariate-adjusted Randomization Design for Clinical Trials. J Biom Biostat. 2016;7:287.
43. Garcia C, et al. Methodological and Ethical Quality Checklist Assessment in Issues of Annals of Family Medicine Clinical Trials (2010-2013). Fam Med Med Sci Res. 2016;5:200.
44. Roever L. Endpoints in Clinical Trials: Advantages and Limitations. Evidence Based Medicine and Practice. 2016;1:e111.
45. Hummel HD, et al. Adverse Events in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Literature Review of Recent Clinical Trials. J Leuk. 2016;4:208.
46. Sjostrand M, et al. Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials. J Diabetes Metab. 2016;7:657.
47. Satty A. An Analysis of Selection Models for Incomplete Longitudinal Clinical Trials Due to Dropout: An Application to Multi-centre Trial Data. Epidemiol. 2016;6:221.
48. Manoj Kumar Sethi. Pharmacovigilance: Challenges in India. J Pharmacovigil. 2016;4:194.
49. Toklu HZ, et al. The Knowledge and Attitude of the Healthcare Professionals towards Pharmacovigilance and Adverse Drug Reaction Reporting in Northern Cyprus. J Pharmacovigilance. 2016;4:193.
50. Obara T, et al. Knowledge of and Perspectives on Pharmacovigilance among Pharmacists in the Miyagi and Hokkaido Regions of Japan. J Pharmacovigilance. 2016;4:192.
51. Magyar I. An Overview on the Third Annual Pharmacovigilance Forum. Clin Pharmacol Biopharm. 2015;5:e122.
52. Kaur I, et al. Effective Reporting by Pharmacist in Pharmacovigilance Programme of India. Adv Pharmacoepidemiol Drug Saf. 2015;4:197.
53. Hama R. The Mechanisms of Adverse Reactions to Oseltamivir: Part II. Delayed Type Reactions. Clin Microbiol. 2015;4:224.
54. Kowalski CJ and Mrdjenovich AJ. Pharmacovigilance Observed: Why Watchful Waiting will Work. J Clin Diagn Res. 2015;3:114.
55. Camacho LH and Pai N. Pharmacovigilance of Oncology Biosimilars. J Pharmacovigilance. 2015;S3:001.
56. Salim M, et al. The Current Perspective of Community Pharmacists towards Pharmacovigilance. J Pharmacovigil. 2015;3:180.
57. Reis CD, et al. Pharmacovigilance in Cabo Verde: Measuring the Awareness and Knowledge by Healthcare Professionals. J Pharmacovigil. 2015;3:177.
58. Ozcagli E, et al. Biosimilar Drugs and Pharmacovigilance. Pharm Anal Acta. 2015;6:416.
59. Chauhan A and Mittu B. An Outlook to Pharmacovigilance in India. Pharm Anal Acta. 2015;6:e179.

60. Yerramilli A, et al. A Pharmacovigilance Study Using Tracer Techniques. Adv Pharmacoepidemiol Drug Saf. 2014;3:165.
61. Maldonado C, et al. Use of STOPP/ START Criteria to Perform Active Pharmacovigilance in the Elderly. J Pharmacovigilance. 2014;2:146.
62. De Ponti F. New Approaches in Pharmacovigilance in the Pharmacogenomic Era: A Call for Papers. J Pharmacovigilance. 2014;2:e122.
63. Allabi AC and Nwokike J. A Situational Analysis of Pharmacovigilance System in Republic of Benin. J Pharmacovigilance. 2014;2:136.
64. Ortiz JAA. Pharmacovigilance Legal Requirements for Marketing Authorization Holders in Spain. J Pharmacovigilance. 2014;2:132.
65. Luisetto et al. Pharmacist Cognitive Service and Pharmaceutical Care: Today and Tomorrow Outlook UKJPB UK. JPB. 2015;3:67-72.
66. de Garbino JP, et al. Evaluation of Antidotes: Activities of the International Programme on Chemical Safety. Clinical Toxicolo. 1997;35:333-343.
67. Nili-Ahmadabadi B, et al. (2016) Clinical Impact of Pharmacist Presence in ICU Medical Team on Mortality clinicinas teamworks bulletin 1.
68. Pollack CV Jr, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511-520.
69. Luisetto, et al. Professional Social Media: Instrument to Meet Researcher and Healthcare. Instruments with a Model for a New Scientific Social Network intern journal of economics and management sciences. Int J Econ Manag Sci. 2016;5:3.
70. Davis K and Stremikis K. Measuring and improving health system performance: what can healthcare management educators do? J Health AdmEduc. 2008;25:05-15.
71. Garman AN, et al. High-performance work systems in health care management, part 1: development of an evidence-informed model.Health Care Manage Rev. 2011;36:201-213.
72. Mauro L and Luca C. Psychological and Behavior Skills for Ph. Care Practice in Medical Team 2016. Human Journals Research Article international journal of pharmacy and pharmaceutical research. 2016;5;1-4.
73. Lin LA. Design and Analysis of Clinical Trials, and Analysis of Correlated Data. J Biom Biostat. 2016;7:280.
74. Liu D, et al. Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol. 2015;6:376.
75. Cummings AL, et al. Low Elderly Participation in Non-Small Cell Lung Cancer Clinical Trials. Gerontol Geriatr Res. 2015;S4:006.
76. Noguchi S, et al. Information Channels and Needs of Health Professionals of Clinical Trials in Japan. J Pharma Care Health Sys. 2015;2:144.
77. Cupertino AP, et al. Knowledge, Awareness, and Interest in Cancer Clinical Trials among Rural Latinos Following Brief Education by Promotores de Salud. J Community Med Health Educ. 2015;5:358.
78. He X, et al. A Simple Method for Estimating Confidence Intervals for Exposur Adjusted Incidence Rate and Its Applications to Clinical Trials. J Biom Biostat. 2015;6:238.
79. Gan TJ, et al. Clinical and Laboratory Hematologic Findings in Patients Receiving Repeated-Dose Injectable HPβCD-Diclofenac for Acute Postoperative Pain: Pooled Analysis of Two Randomized Controlled Phase III Clinical Trials. J Anesth Clin Res. 2015;6:538.
80. Gaus W, et al. Interpretation of Statistical Significance – Exploratory Versus Confirmative Testing in Clinical Trials, Epidemiological Studies, Meta-Analyses and Toxicological Screening (Using Ginkgo biloba as an Example). Clin Exp Pharmacol. 2015;5:182.
81. Ramu B, et al. Current Regulatory Scenario for Conducting Clinical Trials in India. Pharmaceut Reg Affairs 2015;4:140.
82. Egbewale BE. Differences in Sample Size Requirements of Statistical Methods Involved in Clinical Trials with Baseline Imbalance Demonstrated and Quantified: A Simulation Study. J Clin Trials. 2015;5:229.
83. Chang M, et al. Alternative Designs for Phase II Clinical Trials when Attained Sample Sizes are Different from Planned Sample Sizes. J Biomet Biostat. 2015;6:229.
84. Mahady SE, et al. Side effects are incompletely reported among systematic reviews in gastroenterology. J ClinEpidemiol. 2015;68:144-153.
85. Spiegelhalter DJ, et al. Bayesian methods in health technology assessment: a review. Health Technol Assess Winch Engl. 2000;4:1-130.
86. Heitjan DF. Bayesian interim analysis of phase II cancer clinical trials. Stat Med. 1997;16:1791-1802.
87. Lee JJ and Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials LondEngl. 2008;5:93-106.
88. Brannath W, et al. Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration. J Biopharm Stat. 2010;20:1125-1131.
89. Hu F, Rosenberger WF. Introduction- The Theory of Response-Adaptive Randomization in Clinical Trials. John Wiley & Sons Inc, Hoboken, NJ, USA; 2006.

e-ISSN: 2322-0139
p-ISSN: 2322-0120

90. Richards NL, et al. Merging Wildlife and Environmental Monitoring Approaches with Forensic Principles: Application of Unconventional and Non-Invasive Sampling in Eco-Pharmacovigilance. J Forensic Res. 2014;5:228.
91. World Health Organization (2012) Safety monitoring of medicinal products: reporting system for the general public.
92. Stephens MDB. Stephens' Detection of New Adverse Drug Reactions. In: Talbot J, Patrick W, West Sussex, John Wiley & Sons Ltd, London, UK; 2004.
93. FDA's Sentinel Initiative (2013) US Food and Drug Administration. Silver Spring.
94. Toklu HZ. Pharmaceutical Education vs. Pharmacy Practice: Do We Really Teach What They Need For Practicing? J Pharma Care Health Sys. 2015;3:e001.
95. World Health Organization (1985) The Rational Use of Drugs: Report of the Conference of Experts, Nairobi.
96. Rosenberger WF, et al. Adaptive randomization for clinical trials. J Biopharm Stat. 2012;22:719-736.
97. Yin G, et al. Phase II trial design with Bayesian adaptive randomization and predictive probability. Journal of the Royal Statistical Society. 2012;61:219-235.
98. McEntegart DJ. The pursuit of balance using stratified and dynamic randomization techniques: an overview. Drug Information Journal. 2003;37:293-308.